Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi

Future Medicinal Chemistry

Volumn 5, Issue 15, 2013, Pages 1733-1752

  Keenan, Martine ^a   Alexander, Paul W ^a   Chaplin, Jason H ^a   Abbott, Michael J ^a   Diao, Hugo ^a   Wang, Zhisen ^a   Best, Wayne M ^a   Perez, Catherine J ^b   Cornwall, Scott MJ ^b   Keatley, Sarah K ^b   Thompson, RC Andrew ^b   Charman, Susan A ^c   White, Karen L ^c   Ryan, Eileen ^c   Chen, Gong ^c   Ioset, Jean Robert ^d   Von Geldern, Thomas W ^d   Chatelain, Eric ^d  

^a Murdoch University Campus   (Australia)

^b MURDOCH UNIVERSITY   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d Drugs for Neglected Diseases Initiative DNDi   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPROTOZOAL AGENT; BENZNIDAZOLE; CID 1047183; CID 1214515; CID 1867212; CID 2974885; CID 3238629; CID 3774839; CID 4213523; CID 4291888; CID 5025746; CID 5111058; CID 5638819; CID 646158; CID 663315; CID 683024; CID 7694012; POSACONAZOLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CHAGAS DISEASE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; FIBROBLAST; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; LEISHMANIA INFANTUM; LEISHMANIASIS; LIVER MICROSOME; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TRYPANOSOMA CRUZI; TRYPANOSOMA RHODESIENSE;

ADMINISTRATION, ORAL; ANIMALS; CELL LINE; CELL SURVIVAL; CHAGAS DISEASE; CYTOCHROME P-450 CYP3A; DISEASE MODELS, ANIMAL; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICE; PARASITIC SENSITIVITY TESTS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; SURVIVAL RATE; TIME FACTORS; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 84886540022     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.139     Document Type: Article

References (41)

1. Tanowitz HB, Weiss LM, Montgomery SP. Chagas disease has now gone global. PLoS Negl. Trop. Dis. 5(4), e1136 (2011
2. Mitch L. Drug developers finally take aim at a neglected disease. Science 333(19), 933-935 (2011
3. Bahia MT, Andrade IMd, Martins TAF et al. Fexinidazole: A potential new drug candidate for Chagas disease. PloS Negl. Trop. Dis. 6(11), e1870 (2012
4. Apt W, Aguilera X, Arribade A et al. Treatment of chronic Chagas' disease with itraconazole and allopurinol. Am. J. Trop. Med. Hyg. 59(1), 133-138 (1998
5. Molina J, Martins-Filho O, Brener Z, Romanha A, Loebenberg D, Urbina JA. Activities of the triazole derivative SCH 56592 (Posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts. Antimicrob. Agents Chemother. 44(1), 150-155 (2000
6. Urbina JA, Payares G, Sanoja C, Lira R, Romanha AJ. In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease. Int. J. Antimicro. Ag. 21, 27-38 (2003
7. Jean de Ornelas Toledo M, Bahia MT, Carneiro CM et al. Chemotherapy with benznidazole and itraconazole for mice infected with different Trypanosoma cruzi clonal genotypes. Antimicrob. Agents Chemother. 47(1), 223-230 (2003
8. Urbina JA, Payares G, Sanoja C et al. Parasitological cure of acute and chronic experimental Chagas disease using the long-Acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains. Int. J. Antimicrob. Agents 21, 39-48 (2003
9. da Matta Guedes PM, Urbina JA, de Lana M et al. Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts. Antimicrob. Agents Chemother. 48(11), 4286-4292 (2004
10. de Figueiredo Diniz L, Caldas IS, da Matta Guedes PM et al. Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi. Antimicrob. Agents Chemother. 54(7), 2979-2986 (2010
11. Gulin JEN, Eagleson MA, Postan M et al. Efficacy of voriconazole in a murine model of acute Trypanosoma cruzi infection. J. Antimicrob. Chemother. 68(4), 888-894 (2013
12. Kathiravan MK, Salake AB, Chothe AS et al. The biology and chemistry of antifungal agents: A review. Bioorg. Med. Chem. 20(19), 5678-5698 (2012
13. Clayton J. Chagas disease: Pushing through the pipeline. Nature 465, S12-S15 (2010
14. Keenan M, Abbott MJ, Alexander PW et al. Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease. J. Med. Chem. 55, 4189-4204 (2012
15. Keenan M, Alexander PW, Diao H et al. Design, structure-Activity relationship and in vivo efficacy of piperazine analogues of fenarimol as inhibitors of Trypanosoma cruzi. Bioorg. Med. Chem. 21, 1756-1763 (2013
16. Buckner FS, Wilson AJ, White TC, van Voorhis WC. Induction of resistance to azole drugs in Trypanosoma cruzi. Antimicrob. Agents Chemother. 42, 3245-3250 (1998
17. Mejia AM, Hall BS, Taylor MC et al. Benznidazole-resistance in Trypanosoma cruzi is a readily acquired trait that can arise independently in a single population. J. Infect. Dis. 206, 220-228 (2012
18. Zingales B, Miles MA, Campbell DA et al. The revised Trypanosoma cruzi subspecific nomenclature: Rationale, epidemiological relevance and research applications. Infect. Genet. Evol. 12, 240-253 (2012
19. Valadares HMS, Pimenta JR, Segatto M et al. Unequivocal identification of subpopulations in putative multiclonal Trypanosoma cruzi strains by FACs single cell sorting and genotyping. PLoS Negl. Trop. Dis. 6(7), e1722 (2012
20. Torres JP, Ortiz S, Munoz S, Solari A. Trypanosoma cruzi isolates from Chile are heterogeneous and composed of mixed populations when characterized by schizodeme and Southern analyses. Parasitology 128(2), 161-168 (2004
21. Brand S, Cleghorn LAT, McElroy SP et al. Discovery of a novel class of orally active trypanocidal N-myristoyltransferase inhibitors. J. Med. Chem. 55(1), 140-152 (2012
22. Bell AS, Mills JE, Williams GP et al. Selective inhibitors of protozoan protein N-myristoyltransferases as starting points for tropical disease medicinal chemistry programs. PLoS Negl. Trop. Dis. 6(4), e1625 (2012
23. Frearson J, Brand S, McElroy SP et al. N-myristoyltransferase inhibitors as new leads to treat sleeping sickness. Nature 464, 728-732 (2010
24. Buckner FS, Verlinde CL, La Flamme AC, van Voorhis, WC. Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing b-galactosidase. Antimicrob. Agents. Chemther. 40, 2592-2597 (1996
25. Raz B, Iten M, Grether-Buhler Y, Kaminsky R, Brun R. The Alamar Blue® assay to determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. gambiense) in vitro. Acta Trop. 68, 139-147 (1997
26. Lombardo F, Blake JF, Curatolo WJ. Computation of blood-brain partitioning of organic solutes via free energy calculations. J. Med. Chem. 39(24), 4750-4755 (1996
27. Engel JC, Ang KKH, Chen S, Arkin MR, McKerrow JH, Doyle PS. Image-based high-Throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease. Antimicrob. Agents. Chemther. 54(8), 3326-3334 (2010
28. Andriani G, Chessler A-DC, Courtemanche G, Burleigh BA, Rodriguez A. Activity in vivo of anti-Trypanosoma cruzi compounds selected from a high throughput screening. PLoS Negl. Trop. Dis. 5(8), e1298 (2011
29. Sykes ML, Baell JB, Kaiser M et al. Identification of compounds with anti-proliferative activity against Trypanosoma brucei brucei strain 427 by a whole cell viability based HTS campaign. PLoS Negl. Trop. Dis. 6(11), e1896 (2012
30. Chatelain E, Ioset J-R. Drug discovery and development for neglected diseases: The DNDi model. Drug Des. Dev. Ther. 5, 175-181 (2011
31. Chatterjee AK, Yeung BKS. Back to the future: Lessons learned in modern target-based and whole-cell lead optimisation of antimalarials. Curr. Top. Med. Chem. 12(5). 473-483 (2012
32. Germain AR, Carmody LC, Dockendorff C et al. Identification of small-molecule inhibitors of Trypansoma cruzi replication. Bioorg. Med. Chem. Letts. 21 7197-7200 (2011
33. Urbina JA. Chemotherapy of Chagas disease: The how and the why. J. Mol. Med. 77, 332-338 (1999
34. Urbina JA. Specific chemotherapy of Chagas disease: Relevance, current limitations and new approaches. Acta Trop. 115, 55-68 (2010
35. Gunatilleke SS, Calvet CM, Johnston JB et al. Diverse inhibitor chemotypes targeting Trypanosoma cruzi CYP51. PLoS Negl. Trop. Dis. 6(7), e1736 (2012
36. Bettiol E, Samanovic M, Murkin AS, Raper J, Buckner F, Rodriguez A. Identification of three classes of heteroaromatic compounds with activity against intracellular Trypanosoma cruzi by chemical library screening. PLoS Negl. Trop. Dis. 3(2), e384 (2009
37. Sanchez-Moreno M, Gomez-Contreras F, Navarro P et al. Phthalazine derivatives containing imidazole rings behave as Fe-SOD inhibitors and show remarkable anti-T. cruzi activity in immunodeficient-mouse mode of infection. J. Med. Chem. 55, 9900-9913 (2012
38. Andriani G, Amata E, Beatty J et al. Antitrypanosomal lead discovery: Identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth. J. Med. Chem. 56, 2556-2567 (2013
39. Calderon F, Barros D, Bueno JM et al. An invitation to open inovation in malaria drug discovery: 47 quality starting points from the TCAMS. Med. Chem. Lett. 2, 741-746 (2011
40. Rueda L, Castellote I, Castro-Pichel J et al. Cyclopropyl carboxamides: A new oral antimalarial series derived from the Tres Cantos Anti-Malarial Set (TCAMS). Med. Chem. Lett. 2, 840-844 (2011
41. Lepesheva GI, Waterman MR. Sterol 14alpha-demethylase (CYP51) as a therapeutic target for human trypanosomiasis and leishmaniasis. Curr. Top. Med. Chem. 11(16), 2060-2071 (2011